For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
"PIMAVANSERIN - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Major depressive disorder in 7 Major Markets. A detailed picture of the PIMAVANSERIN in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
Overview
PIMAVANSERIN is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in psychosis, schizophrenia, depression and other neuropsychiatric disorders. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis by the U.S. Food and Drug Administration in April 2016 under the trade name NUPLAZID. NUPLAZID is not approved for dementia-related psychosis, schizophrenia or major depressive disorder.
Scope of the report
The report provides insights into:
- A comprehensive product
Overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
- Elaborated details on regulatory milestones and other development activities have been provided in this report.
- The report also highlights the drug research and development activity details across the United States, Europe and Japan.
- The report also covers the patents information with expiry timeline around PIMAVANSERIN.
- The report contains forecasted sales for PIMAVANSERIN till 2030.
- Comprehensive coverage of the late-stage emerging therapies (Phase III) for Major depressive disorder.
- The report also features the SWOT analysis with analyst insights and key findings of PIMAVANSERIN.
Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
PIMAVANSERIN Analytical Perspective by DelveInsight
- In-depth PIMAVANSERIN Market Assessment
This report provides a detailed market assessment of PIMAVANSERIN in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
- PIMAVANSERIN Clinical Assessment
The report provides the clinical trials information of PIMAVANSERIN covering trial interventions, trial conditions, trial status, start and completion dates.
Report highlights
- In the coming years, the market scenario for Major depressive disorder is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence PIMAVANSERIN dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Other emerging products for Major depressive disorder are giving market competition to PIMAVANSERIN and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of PIMAVANSERIN.
- Our in-depth analysis of the forecasted sales data of PIMAVANSERIN from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PIMAVANSERIN.
Key Questions
- Which company is developing PIMAVANSERIN along with the phase of the clinical study?
- What is the technology utilized in the development of PIMAVANSERIN?
- What is the product type, route of administration and mechanism of action of PIMAVANSERIN?
- What is the clinical trial status of the study and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PIMAVANSERIN development?
- What are the key designations that have been granted to PIMAVANSERIN?
- What is the forecasted market scenario of PIMAVANSERIN?
- What is the history of PIMAVANSERIN and what is its future?
- What is the forecasted sales of PIMAVANSERIN in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
- What are the other emerging products available and how these are giving competition to PIMAVANSERIN?
- Which are the late-stage emerging therapies under development for the treatment of Major depressive disorder?